NAPSR news: J & J and Glaxo (ViiV Healthcare) join forces to develop HIV combo treatment

The new collaborative effort to develop a single tablet for HIV treatment by industry leaders J &J and Glaxo (Viiv Healthcare) could significantly improve the lives of HIV patients, if successful.
Spread the Word
Listed Under

Pharmaceutical Sales
Pharmaceutical Sales Training
Pharmaceutical Sales Rep


Washington - District of Columbia - US

WASHINGTON - June 18, 2014 - PRLog -- Johnson & Johnson has signed a deal with Viiv Healthcare to collaborate on a new single tablet that incorporates two anti viral treatments. The development of this tablet will theoretically spare HIV patients from some harsh side effects associated with current therapies. The combination therapy plan will include J&J's rilpivirine, which prevents HIV from replicating itself in cells, and ViiV's dolutegravir which blocks an enzyme that allows the virus to crack its host's DNA.

If this collaboration on a single tablet is indeed successful – this will without a doubt challenge Gilead Sciences' dominance in the field. Gilead’s Atripla which contains two NRTIs (nucleoside reverse transcriptase inhibitors) EMTRIVA (emtricitabine) and VIREAD (tenofovir disoproxil fumarate) with one NNRTI (non-nucleoside reverse transcriptase inhibitor) SUSTIVA (efavirenz) is currently the leading treatment, pulling in $3.6 billion last year, according to Fierce Biotech.

A single tablet combo could drastically improve the lives of virologically suppressed HIV patients, the companies said. J&J's rilpivirine, a non-NRTI, claims the same replication-blocking capability will spare HIV patients the jarring side effects that may be experienced with other therapies. By also adding in dolutegravir, an integrase inhibitor, this could give HIV patients a more simplified treatment.

ViiV CMO Dr. John Pottage stated "New options that advance current therapies are increasingly important as patients and clinicians consider HIV care over the long term,"

With such industry leaders paving the way for the advancement of beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their product, once approved. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES! Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.

Email:*** Email Verified
Tags:Education, Pharmaceutical Sales, Cnpr, Pharmaceutical Sales Training, Pharmaceutical Sales Rep
Industry:Education, Health
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share